
Description: This industry offers a 6-year forecast of the global pharmacovigilance market between 2015 and 2020. In terms of value, the market is expand at a CAGR of 14.2% during the forecast period. This study demonstrates market dynamics and trends in all seven regions that are expected to influence the current environment and future status of the pharmacovigilance market over the forecast period.

Report Description

This report examines the pharmacovigilance market for the period 2015-2020. The primary objective of the report is to offer insights into developments in the pharmacovigilance market that are significantly transforming global businesses and enterprises.

The global pharmacovigilance market report begins by defining pharmacovigilance and its various segments. This is followed by an overview of the global pharmacovigilance market. The overview section includes analysis of key trends, drivers, restraints, trends and opportunities that are influencing growth of the pharmacovigilance market currently. It also includes information related to the market shares of the major players in the market. Impact analyses of key growth drivers and restraints based on the weighted average model have been included in this report on the global pharmacovigilance market to better equip customers and readers with region specific trends and insights.

The primary driving factor for growth of the pharmacovigilance market is the significant increase witnessed in the intake of medical drugs. Besides, increase in prevalence of acute and chronic diseases has consequently led to an increase in incidences of drug consumption, thereby leading to a rise in the number of adverse drug events and drug toxicity cases. This, in turn, has triggered the growth of the pharmacovigilance market globally. Furthermore, safety regulations, risk of high-profile safety issues and need to review large volume of post-market events along with negative media coverage have compelled the pharmaceutical players to take support of various outsourcing services for drug monitoring. Factors such as intensifying regulatory expectations, tougher inspection system and instant need for patient reporting are boosting the adoption rate of pharmacovigilance among pharmaceutical companies globally. Pharmaceutical companies are now entering into long-term partnerships/service agreements with CROs and BPOs to reduce the pharmacovigilance process related expenditure, incurred right from drug discovery to post-marketing approvals.

The global pharmacovigilance market is segmented based on phase of drug development, type of reporting methods and type of service providers. On the basis of phase of drug development, the market has been segmented into preclinical studies, phase I clinical trial, phase II clinical trial, phase III clinical trial and phase IV clinical trial or post-marketing surveillance. On the basis of type of reporting methods, the market has been segmented into spontaneous reporting, intensified ADR reporting, targeted spontaneous reporting, cohort event monitoring and EHR mining. On the basis of the type of service providers, the market has been segmented into in-house and contract outsourcing. A detailed analysis has been provided for all segments and sub-segments in terms of market size, Y-o-Y growth rate, absolute $ opportunity and BPS analysis.

A deep market analysis along with market attractiveness index for each of the categories have been provided in the report. The next section of the report highlights the pharmacovigilance market by region. It provides a market outlook for 2015-2020 and sets the forecast within the context of the pharmacovigilance market. The study discusses key regional trends contributing to growth of the pharmacovigilance market worldwide, as well as analyses the extent to which the drivers are influencing this market in each region. Key regions assessed in this report include North America, Latin America, Western Europe, Eastern Europe, Asia Pacific Excluding Japan (APEJ), Japan and the Middle East & Africa.

The above sections, by phase of drug development, type of reporting methods and type of service providers and region, evaluate the present scenario and growth prospects of the pharmacovigilance market for the period 2015–2020. We have considered 2014 as the base year and provided data for the forecast period, i.e. 2015–2020.
To ascertain the market size of pharmacovigilance, we have also considered revenue generated by pharmacovigilance companies. The forecast presented here assesses the total revenue generated across the pharmacovigilance market. In order to offer an accurate forecast, we started by sizing the current market, which forms the basis of how the pharmacovigilance market is expected to develop in the future. Given the characteristics of the market, we triangulated the outcome of three different types of analysis, based on supply side, downstream industry demand and the economic envelope.

In addition, it is imperative to note that in an ever-fluctuating global economy, we not only conduct forecasts in terms of CAGR, but also analyse the market based on key parameters, such as Year-on-Year (Y-o-Y) growth rates, to understand the predictability of the market and to identify the right growth opportunities in the market.

In this report, the pharmacovigilance market is segmented in terms of phase of drug development, type of reporting methods, type of service providers and region. These segments are analysed in terms of Basis Point Share (BPS) to understand individual segment’s relative contributions to market growth. This detailed level of information is important for identification of various key trends in the pharmacovigilance market.

Another key feature of this report is the analysis of key segments in terms of absolute dollar opportunity. This is traditionally overlooked while forecasting the market. However, absolute dollar opportunity is critical for assessing the level of opportunity that a provider can look to achieve, as well as to identify potential resources from a sales and delivery perspective of the pharmacovigilance market.

To understand key growth segments in terms of growth across the globe in the near future, this industry developed the pharmacovigilance market attractiveness index. The resulting index should help providers identify real market opportunities.

In the final section of the report, the ‘Competitive Landscape’ of the market is included to provide report audiences with a dashboard view, based on categories of providers in the value chain of the pharmacovigilance product portfolio and key differentiators. Key categories of providers covered in the report are pharmacovigilance companies. This section is primarily designed to provide clients with an objective and detailed comparative assessment of key providers specific to a market segment of the pharmacovigilance value chain and the potential players with respect to the same. Report audiences can gain segment-specific vendor insights to identify and evaluate key competitors based on their in-depth assessment of capabilities and successes in the pharmacovigilance marketplace.


Key Segments Covered

By Phases of Drug Development
Preclinical Studies
Phase I
Phase II
Phase III
Phase IV or Post Marketing Surveillance

By Type of Method
Spontaneous Reporting
Intensified ADR Reporting
Targeted Spontaneous Reporting
Cohort Event Monitoring
EHR Mining

By Type of Service Provider
In-house Pharmacovigilance
Contract Outsourcing

Key Regions/Countries Covered

North America
U.S.
Canada
Latin America
Brazil
Argentina
Mexico
Rest of Latin America
Western Europe
U.K.
France
Germany
Spain
Italy
Nordics
BENELUX
Rest of Western Europe
Eastern Europe
Poland
Russia
Rest of Eastern Europe
Asia Pacific Excluding Japan (APEJ)
Greater China
India
ASEAN
Australia and New Zealand
Rest of APEJ
Japan
Middle East & Africa
GCC
South Africa
Rest of MEA

Key Companies

Accenture plc
Bristol-Myers Squibb
Clinquest Group B.V.
Cognizant Technology Solutions
Covance, Inc.
Hoffmann-La Roche Ltd.
GlaxoSmithKline plc (GSK)
ICON plc
iGATE Corporation
iMEDGlobal Corporation
inVentiv Health, Inc.
Novartis International AG
PAREXEL International Corporation
Pfizer, Inc.
Pharmaceutical Product Development, LLC. (PPD)
PRA Health Sciences, Inc.
Quintiles Transnational Holdings, Inc.
Sanofi A.
Synowledge LLC
Wipro Limited

Contents: Chapter 1 Introduction
Chapter 2 Executive Summary

Chapter 3 Global Pharmacovigilance Market Dynamics
3.1 Introduction
3.2 Market Drivers
3.2.1 Increasing Consumption of Drugs Would Fuel Demand for Continuous Drug Event Monitoring
3.2.2 Rise in the Cases of Adverse Drug Reactions and Drug Toxicity Would Boost Demand for Pharmacovigilance Activities
3.2.3 Rise in Adoption of Outsourcing Services Expected to Accentuate the Market Growth
3.3 Market Restraints
3.3.1 High Risk Associated with Data Security in Pharmacovigilance Outsourcing
3.3.2 Lack of Availability of Skilled Labor might Hinder the Market Growth
3.3.3 Inadequate Pharmacovigilance System for Herbal Products in Asia Pacific Might Hamper the Market Growth
3.4 Market Opportunities
3.4.1 Huge Scope for Rapid Growth of Pharmacovigilance Market in Emerging Economies
3.4.2 Shift in Preference for Outsourcing among Various Pharmaceutical and Life Sciences Companies
3.5 Porter's Five Forces Analysis: Global Pharmacovigilance Market
3.5.1 Bargaining Power of Suppliers
3.5.2 Bargaining Power of Buyers
3.5.3 Threat of Substitutes
3.5.4 Threat of New Entrants
3.5.5 Competitive Rivalry
3.6 Market Attractiveness Analysis: Global Pharmacovigilance Market, by Geography
3.7 Competitive Landscape
3.7.1 Market Share Analysis: Global Pharmacovigilance Market, 2013 (Value %)

Chapter 4 Global Pharmacovigilance Market, by Phases of Drug Development
4.1 Overview
4.1.2 Comparative Analysis: Global Pharmacovigilance Market Revenue, by Type of Clinical Trial Phases, 2013 & 2020 (Value %)
4.2 Preclinical Studies
4.2.1 Global Preclinical Studies Pharmacovigilance Market Revenue, 2012 – 2020 (USD Million)
4.3 Phase I
4.3.1 Global Phase I Clinical Trial Pharmacovigilance Market Revenue, 2012 – 2020 (USD Million)
4.4 Phase II
4.4.1 Global Phase II Clinical Trial Pharmacovigilance Market Revenue, 2012 – 2020 (USD Million)
4.5 Phase III
4.5.1 Global Phase III Clinical Trial Pharmacovigilance Market Revenue, 2012 – 2020 (USD Million)
4.6 Phase IV or Post Marketing Surveillance
4.6.1 Global Phase IV Clinical Trial Pharmacovigilance Market Revenue, 2012 – 2020 (USD Million)

Chapter 5 Global Pharmacovigilance Market, By Type of Methods
5.1 Overview
5.1.1 Global Pharmacovigilance Market Revenue, by Type of Methods , 2012 – 2020 (USD Million)
5.1.2 Comparative Analysis: Global Pharmacovigilance Market Revenue, by Type of Methods, 2013 & 2020 (Value %)
5.2 Spontaneous Reporting
5.2.1 Global Spontaneous Reporting Market Revenue, 2012 – 2020 (USD Million)
5.3 Intensified ADR Reporting
5.3.1 Global Intensified ADR Reporting Market Revenue, 2012 – 2020 (USD Million)
5.4 Targeted Spontaneous Reporting
5.4.1 Global Targeted Spontaneous Reporting Market Revenue, 2012 – 2020 (USD Million)
5.5 Cohort Event Monitoring
5.5.1 Global Cohort Event Monitoring Market Revenue, 2012 – 2020 (USD Million)
5.6 EHR Mining
5.6.1 Global EHR Mining Market Revenue, 2012 – 2020 (USD Million)
Chapter 6 Global Pharmacovigilance Market, by Type Service Providers
6.1 Overview
6.1.1 Global Pharmacovigilance Market Revenue, by Type of Service Providers, 2012–2020 (USD Million)
6.1.2 Comparative Analysis: Global Pharmacovigilance Market, by Type of Service Providers, 2013 & 2020 (Value %)
6.2 In-house Pharmacovigilance
6.2.1 Global In-House Pharmacovigilance Market Revenue, 2012 – 2020 (USD Million)
6.3 Contract Outsourcing
6.3.1 Global Contract Outsourcing Pharmacovigilance Market Revenue, 2012 – 2020 (USD Million)

Chapter 7 Global Pharmacovigilance Market, by Geography
7.1 Overview
7.1.1 Global Pharmacovigilance Market Revenue, by Geography, 2012 – 2020 (USD Million)
7.2 North America
7.2.1 North America Pharmacovigilance Market Revenue, 2012 - 2020 (USD Million)
7.3 Europe
7.3.1 Europe Pharmacovigilance Market Revenue, 2012 - 2020 (USD Million)
7.4 Asia Pacific
7.4.1 Asia Pacific Pharmacovigilance Market Revenue, 2012 - 2020 (USD Million)
7.5 Rest of the World (RoW)
7.5.1 RoW Pharmacovigilance Market Revenue, 2012 - 2020 (USD Million)

Chapter 8 Recommendations
8.1 Market Strategy
8.1.1 Strategic Partnerships and Collaborations With CROs And Life Sciences BPOs
8.1.2 Optimization of Drug Safety Through Hub and Spoke Model
8.1.3 Developing Operational Activities for Better Outcomes
8.1.4 Regional Expansion

Chapter 9 Company Profiles
9.1 Accenture plc
9.1.1 Company Overview
9.1.2 Financial Overview
9.1.3 Product Portfolio
9.1.4 Business Strategies
9.1.4.1 Mergers and acquisitions
9.1.5 Recent Developments
9.2 Bristol-Myers Squibb
9.2.1 Company Profile
9.2.2 Financial Overview
9.2.3 Product Portfolio
9.2.4 Business Strategies
9.2.4.1 Strategic collaboration and acquisitions
9.2.4.2 Research and Development Initiatives
9.2.4.3 Recent Developments
9.3 Clinquest Group B.V.
9.3.1 Company Overview
9.3.2 Financial Overview
9.3.3 Product Portfolio
9.3.4 Business Strategies
9.3.4.1 Strategic partnership
9.3.5 Recent Developments
9.4 Cognizant Technology Solutions
9.4.1 Company Overview
9.4.2 Financial Overview
9.4.3 Product Portfolio
9.4.4 Business Strategies
9.4.4.1 Expansion of geographical footprint
9.4.4.2 Expansion of product portfolio
9.4.4.3 Highly-skilled manpower
9.4.4.4 Strategic acquisitions
9.4.5 Recent Developments
9.5 Covance, Inc.
9.12.4.2 Expansion of product portfolio through research and development
9.12.5 Recent Developments
9.13 PAREXEL International Corporation
9.13.1 Company Overview
9.13.2 Financial Overview
9.13.3 Product Portfolio
9.13.3.1 Strong presence in Asia and emerging markets
9.13.3.2 Strategic alliances
9.13.3.3 Mergers & acquisitions
9.13.4 Recent Developments
9.14 Pfizer, Inc.
9.14.1 Company Overview
9.14.2 Financial Overview
9.14.3 Product Portfolio
9.14.4 Business Strategies
9.14.4.1 Acquisitions
9.14.4.2 Research and development
9.14.5 Recent Developments
9.15 Pharmaceutical Product Development, LLC. (PPD)
9.15.1 Company Overview
9.15.2 Financial Overview
9.15.3 Product Portfolio
9.15.4 Business Strategies
9.15.4.1 Geographic expansion
9.15.4.2 Strategic collaboration
9.15.4.3 Strategic partnership
9.15.4.4 Strategic acquisitions
9.15.5 Recent Developments
9.16 PRA Health Sciences, Inc.
9.16.1 Company Overview
9.16.2 Financial Overview
9.16.3 Product Portfolio
9.16.4 Business Strategies
9.16.4.1 Mergers and acquisitions
9.16.5 Recent Developments
9.17 Quintiles Transnational Holdings, Inc.
9.17.1 Company Overview
9.17.2 Financial Overview
9.17.3 Product Portfolio
9.17.4 Business Strategies
9.17.4.1 Acquisitions and partnerships
9.17.5 Recent Developments
9.18 Sanofi
9.18.1 Company Overview
9.18.2 Financial Overview
9.18.3 Product Portfolio
9.18.4 Business Strategies
9.18.4.1 Renewal of cooperation protocol
9.18.5 Recent developments
9.19 Synowledge LLC
9.19.1 Company Overview
9.19.2 Financial Overview
9.19.3 Product Portfolio
9.19.4 Business Strategies
9.19.4.1 Geographical expansion
9.19.4.2 Strategic Partnership
9.19.5 Recent Developments
9.20 Wipro Limited
9.20.1 Company Overview
9.20.2 Financial Overview
9.20.3 Product Portfolio
9.20.4 Business Strategies
9.20.4.1 Geographical expansion
List of Figures

FIG. 1 Drug Safety from Molecule to Market
FIG. 2 Pharmacovigilance: Market Segmentation
FIG. 3 Global Pharmacovigilance Market, by Phases of Drug Development, 2013 (USD Million)
FIG. 4 Global Pharmacovigilance Market, by Type of Service Providers, 2013 (USD Million)
FIG. 5 Global Pharmacovigilance Market, by Type of Methods, 2013 (USD Million)
FIG. 6 Comparative Analysis: Global Pharmacovigilance Market, by Geography, 2103 (Value %)
FIG. 7 Porter's Five Forces Analysis: Global Pharmacovigilance Market
FIG. 8 Market Attractiveness Analysis: Global Pharmacovigilance Market, by Geography (2013)
FIG. 9 Global Pharmacovigilance Market Share Analysis, by Key Players, 2013 (%)
FIG. 10 Safety Services : Product Lifecycle
FIG. 11 Comparative Analysis: Global Pharmacovigilance Market Revenue, by Phases of Drug Development, 2013 & 2020 (Value %)
FIG. 12 Global Preclinical Studies Pharmacovigilance Market Revenue, 2012 – 2020 (USD Million)
FIG. 13 Global Phase I Clinical Trial Pharmacovigilance Market Revenue, 2012 – 2020 (USD Million)
FIG. 14 Global Phase II Clinical Trial Pharmacovigilance Market Revenue, 2012 – 2020 (USD Million)
FIG. 15 Global Phase III Clinical Trial Pharmacovigilance Market Revenue, 2012 – 2020 (USD Million)
FIG. 16 Global Phase IV Clinical Trial Pharmacovigilance Market Revenue, 2012 – 2020 (USD Million)
FIG. 17 Comparison of Methods: Pharmacovigilance reporting
FIG. 18 Comparative Analysis: Global Pharmacovigilance Market Revenue, by Type of Methods, 2013 & 2020 (Value %)
FIG. 19 Global Spontaneous Reporting Market Revenue, 2012 – 2020 (USD Million)
FIG. 20 Global Intensified ADR Reporting Market Revenue, 2012 – 2020 (USD Million)
FIG. 21 Global Targeted Spontaneous Reporting Market Revenue, 2012 – 2020 (USD Million)
FIG. 22 Global Cohort Event Monitoring Market Revenue, 2012 – 2020 (USD Million)
FIG. 23 Global EHR Mining Market Revenue, 2012 – 2020 (USD Million)
FIG. 24 End-to-End Safety Across the Lifecycle
FIG. 25 Comparative Analysis: Global Pharmacovigilance Market, by Type of Service Providers, 2013 & 2020 (Value %)
FIG. 26 Global In-House Pharmacovigilance Market Revenue, 2012 – 2020 (USD Million)
FIG. 27 Global Contract Outsourcing Pharmacovigilance Market Revenue, 2012 – 2020 (USD Million)
FIG. 28 North America Pharmacovigilance Market Revenue, 2012 – 2020 (USD Million)
FIG. 29 Europe Pharmacovigilance Market Revenue, 2012 – 2020 (USD Million)
FIG. 30 Asia Pacific Pharmacovigilance Market Revenue, 2012 – 2020 (USD Million)
FIG. 31 RoW Pharmacovigilance Market Revenue, 2012 – 2020 (USD Million)
FIG. 32 Accenture plc.: Annual Revenue 2011 – 2013 (USD Billion)
FIG. 33 Bristol-Myers Squibb: Annual Revenue, 2011 – 2013 (USD Million)
FIG. 34 Cognizant Technology Solutions: Annual Revenue, 2011 – 2013 (USD Million)
FIG. 35 COVANCE, Inc.: Annual Revenue, 2011 – 2013 (USD Million)
FIG. 36 F. Hoffmann-La Roche Ltd., Annual Revenue: 2011 – 2013 (USD Million)
FIG. 37 GlaxoSmithKline plc (GSK): Annual Revenue, 2011 – 2013 (USD Million)
FIG. 38 ICON plc: Annual Revenue, 2011 – 2013 (USD Million)
FIG. 39 iGATE Corporation: Annual Revenue, 2011 – 2013 (USD Million)
FIG. 40 Novartis International AG: Annual Revenue, 2011 – 2013 (USD Million)
FIG. 41 PAREXEL International Corporation: Annual Revenue 2011 – 2013 (USD Million)
FIG. 42 Pfizer, Inc.: Annual Revenue, 2011 – 2013 (USD Million)
FIG. 43 PRA Health Sciences, Inc., Annual Revenue: 2012 – 2014 (USD Million)
FIG. 44 Quintiles Transnational Holdings, Inc.: Annual Revenue, 2011 – 2013 (USD Million)
FIG. 45 Sanofi: Annual Revenue, 2011 – 2013 (USD Million)
FIG. 46 Wipro Limited: Annual Revenue 2011 – 2013 (USD Million)

List of Tables

TABLE 1 Global PA market snapshot
TABLE 2 Drivers for Phthalic Anhydride market: impact analysis
TABLE 3 Restraints for phthalic anhydride market : impact analysis
TABLE 4 North America PA market, volume, by application segment, 2012 – 2019 (Kilo Tons)
TABLE 5 North America market for PA, revenue, by application segment, 2012 – 2019 (USD Million)
TABLE 6 Europe PA market, volume, by application segment, 2012 – 2019 (Kilo Tons)
TABLE 7 Europe PA market, revenue, by application segment, 2012 – 2019 (USD Million)
TABLE 8 Asia Pacific PA market, volume, by application segment, 2012 – 2019 (Kilo Tons)
TABLE 9 Asia Pacific PA market, revenue, by application segment, 2012 – 2019 (USD Million)
TABLE 10 ROW PA market, volume, by application segment, 2012 – 2019 (Kilo Tons)
TABLE 11 ROW PA market, revenue, by application segment, 2012 – 2019 (USD Million)

Ordering:
Order Online - http://www.researchandmarkets.com/reports/3517163/
Order by Fax - using the form below
Order by Post - print the order form below and send to

Research and Markets,
Guinness Centre,
Taylors Lane,
Dublin 8,
Ireland.
Fax Order Form
To place an order via fax simply print this form, fill in the information below and fax the completed form to 646-607-1907 (from USA) or +353-1-481-1716 (from Rest of World). If you have any questions please visit
http://www.researchandmarkets.com/contact/

Order Information
Please verify that the product information is correct and select the format(s) you require.

Web Address: http://www.researchandmarkets.com/reports/3517163/
Office Code: SCH38117

Product Formats
Please select the product formats and quantity you require:

<table>
<thead>
<tr>
<th>Quantity</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Electronic (PDF) - Single User</td>
<td>USD 5000</td>
</tr>
<tr>
<td>Electronic (PDF) - Site License</td>
<td>USD 7500</td>
</tr>
<tr>
<td>Electronic (PDF) - Enterprisewide</td>
<td>USD 10000</td>
</tr>
</tbody>
</table>

Contact Information
Please enter all the information below in BLOCK CAPITALS

Title: Mr □ Mrs □ Dr □ Miss □ Ms □ Prof □
First Name: __________________________ Last Name: __________________________
Email Address: * __________________________
Job Title: __________________________
Organisation: __________________________
Address: __________________________
City: __________________________
Postal / Zip Code: __________________________
Country: __________________________
Phone Number: __________________________
Fax Number: __________________________

* Please refrain from using free email accounts when ordering (e.g. Yahoo, Hotmail, AOL)
Payment Information

Please indicate the payment method you would like to use by selecting the appropriate box.

☐ Pay by credit card: You will receive an email with a link to a secure webpage to enter your credit card details.

☐ Pay by check: Please post the check, accompanied by this form, to:

Research and Markets,
Guinness Center,
Taylors Lane,
Dublin 8,
Ireland.

☐ Pay by wire transfer: Please transfer funds to:

<table>
<thead>
<tr>
<th>Account number</th>
<th>833 130 83</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sort code</td>
<td>98-53-30</td>
</tr>
<tr>
<td>Swift code</td>
<td>ULSBIE2D</td>
</tr>
<tr>
<td>IBAN number</td>
<td>IE78ULSB98533083313083</td>
</tr>
<tr>
<td>Bank Address</td>
<td>Ulster Bank, 27-35 Main Street, Blackrock, Co. Dublin, Ireland</td>
</tr>
</tbody>
</table>

If you have a Marketing Code please enter it below:

Marketing Code: ______________________

Please note that by ordering from Research and Markets you are agreeing to our Terms and Conditions at http://www.researchandmarkets.com/info/terms.asp

Please fax this form to:
(646) 607-1907 or (646) 964-6609 - From USA
+353-1-481-1716 or +353-1-653-1571 - From Rest of World